Australia is anticipating the availability of Retatrutide, a innovative medication by Novo Nordisk. This twin-action drug, targeting both GLP-1 and GIP receptors, demonstrates impressive efficacy in clinical trials, https://wearethelist.com/story24180426/this-new-drug-retatrutide-australia-a-potential-solution-for-weight-management